{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-108806","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.430560+00:00","generated_at":"2026-05-16T22:19:53.839311+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ironwood Q3 LINZESS sales up 40% YoY to $315M; raises full-year guidance","bullets":["Q3 GAAP net income $40M ($0.23 diluted EPS) vs $3.6M a year ago; adjusted EBITDA $82M vs $34.5M.","LINZESS US net sales $315M (+40% YoY); EUTRx demand growth +12% YoY.","Raises FY2025 LINZESS net sales guidance to $860-$890M; total revenue $290-$310M; adjusted EBITDA >$135M.","FDA approved LINZESS for IBS-C in children ages 7+; first drug for that indication.","Plans to align with FDA on apraglutide Phase 3 trial design, start confirmatory study H1 2026; strategic alternatives review ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-108806","json":"https://secwatch.observer/filing/0001104659-25-108806.json","markdown":"https://secwatch.observer/filing/0001104659-25-108806.md","text":"https://secwatch.observer/filing/0001104659-25-108806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/0001104659-25-108806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925108806/tm2530577d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:19:53.839311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}